Emergent Serum Therapy and Antibody Medicine to Counteract Sudden Attacks of COVID-19 and Other Pathogenic Epidemics

Journals Menu

Follow SCIRP

ISSN Print: 2169-2513
ISSN Online: 2169-2521
www.scirp.org/journal/ojrm
E-mail: ojrm@scirp.org

"Emergent Serum Therapy and Antibody Medicine to Counteract Sudden Attacks of COVID-19 and Other Pathogenic Epidemics"
written by Peter K. Law,
published by Open Journal of Regenerative Medicine, Vol.9 No.1, 2020

has been cited by the following article(s):

[1]	Immune-Based Therapy for COVID-19
	2021

[2]	Convalescent Blood: Current Perspective on the Efficacy of a Legacy Approach in COVID-19 Treatment
	2021

[3]	Advances in immunotherapy for COVID-19: A comprehensive review
	2021

[4]	Sars-cov-2 y sus efectos en el primer trimestre en Argentina
	2021

[5]	Gender vulnerability towards the COVID-19 Pandemic
	2020

[6]	System Engineering of Emergent Serum Therapy to Combat COVID-19 and Other Pathogenic Pandemics
	2020

[7]	Re-examination of An Integrative Treatment Approach for SARS-CoV-2
	2020

[8]	Convalescent plasma: can it be a promising biological rescue option for severe COVID-19?
	2020

[9]	COVID-19 Pandemic: Its Origin, Implications and Treatments
	2020

[10]	Novel Coronavirus (COVID-19) Treatment Options
	2020

[11]	COVID-19: Transmission, prevention, and potential therapeutic opportunities
	2020

[12]	Flavonols as potential antiviral drugs targeting SARS-CoV-2 proteases (3CLpro and PLpro), spike protein, RNA-dependent RNA polymerase (RdRp) and angiotensin …
	2020

[13]	The Pandemic of Novel Coronavirus Disease 2019 (COVID-19): Need for an Immediate Action
	2020

[14]	Harmony of operations of some vitamins in controlling the 2019-nCoV virus based on scientific reports
	2020

[1]	Handbook of Stem Cell Therapy 2022 DOI:10.1007/978-981-16-6016-0_34-1

[2]	Handbook of Stem Cell Therapy 2022 DOI:10.1007/978-981-19-2655-6_34

[3]	Handbook of Stem Cell Therapy 2022 DOI:10.1007/978-981-16-6016-0_34-1

[4]	Flavonols as potential antiviral drugs targeting SARS-CoV-2 proteases (3CLpro and PLpro), spike protein, RNA-dependent RNA polymerase (RdRp) and angiotensin-converting enzyme II receptor (ACE2) European Journal of Pharmacology, 2021 DOI:10.1016/j.ejphar.2020.173759

[5]	Coronavirus Disease - COVID-19 Advances in Experimental Medicine and Biology, 2021 DOI:10.1007/978-3-030-63761-3_26

[6]	Coronavirus Disease - COVID-19 Advances in Experimental Medicine and Biology, 2021 DOI:10.1007/978-3-030-63761-3_26

[7]	Flavonols as potential antiviral drugs targeting SARS-CoV-2 proteases (3CLpro and PLpro), spike protein, RNA-dependent RNA polymerase (RdRp) and angiotensin-converting enzyme II receptor (ACE2) European Journal of Pharmacology, 2021 DOI:10.1016/j.ejphar.2020.173759

[8]	COVID-19: Transmission, prevention, and potential therapeutic opportunities Clinica Chimica Acta, 2020 DOI:10.1016/j.cca.2020.05.044

Follow SCIRP